Developer docs
API playgroundTry for free, no card

Search company profiles

Epibiotech

Full company profile

uuid0003o8k

Namestring
Epibiotech
Legal namestring
주식회사 에피바이오텍 (Epibiotech Co., Ltd.)
Websiteurl
epibiotech.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Epibiotech (에피바이오텍, KONEX: 446440) is a South Korean biotech company founded in 2015 (originally as Stemore Co., Ltd., renamed in 2021) that operates as the only Korean firm exclusively dedicated to hair loss therapeutics development. The company is built around its proprietary Hair.I. integrated drug discovery platform, which combines three modules: EPIGene (Korea's only alopecia-specific genomic database with single-cell RNAseq resolution across disease types and species), AlopeciAI (a multi-target AI screening platform with drug repurposing capability), and EPICacy (a hair growth efficacy evaluation platform using Korea's largest collection of alopecia animal models). Epibiotech runs a multi-modality therapeutic pipeline spanning autologous and allogeneic dermal papilla cell therapies (EPI-001 in Phase 1/2a clinical trials; EPI-008 in preclinical with a cell bank scalable to 100,000 patients), a CXCL12 neutralizing antibody (EPI-005), and drug repurposing candidates for chemotherapy-induced alopecia (EPI-011) and topical small molecule treatment (EPI-002).

The company generates revenue across four streams: (1) CRO services for hair growth efficacy evaluation and mechanism studies (30+ contract studies annually, fee-for-service, quote-based pricing), (2) cell line product sales (STC001-STC011 covering dermal papilla cells, ORS cells, adipose-derived stem cells, and engineered reporter cell lines), (3) CDMO services for GMP cell therapy manufacturing from a 495m² GMP facility in Songdo, and (4) hair health functional food evaluation services aligned with Korean regulatory guidelines. Customer segments include pharmaceutical and biotech companies (primary, for preclinical CRO and CDMO), research institutions and academia, and cosmetics and functional food companies. Distribution combines direct B2B field sales, global partnering conference presence (BIO Europe, BIO Japan, WCHR, KDRA), website-based inquiry for CRO/cell line sales, and an exclusive China-market partnership with Beijing Northland. The company holds advanced biopharmaceutical manufacturing, cell processing, and human cell management licenses, has been designated an Outstanding R&D Center by Korea's Ministry of Science and ICT, and has received awards from KHIDI, the Ministry of SMEs and Startups, and AbbVie Korea.

Short descriptiontext

Epibiotech is South Korea's only company exclusively dedicated to hair loss therapeutics, operating an AI-driven drug discovery platform (Hair.I.) across cell therapy, antibody, and small molecule pipelines, complemented by a leading domestic non-clinical CRO, CDMO services, and cell line product sales for pharmaceutical and biotech clients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIncheon, South Korea
HQ citystring
Incheon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hair loss therapeutics, drug discovery platform, preclinical CRO services, cell therapy manufacturing, dermal papilla cells
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Hair Loss Therapeutics & Preclinical Drug Discovery CRO
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1CRO (Contract Research Organization) Services
TypeProfessional Services
Description

Hair growth efficacy evaluation and preclinical research services provided to pharmaceutical companies, biotech firms, and research institutions. Services include in vitro, ex vivo, and in vivo models for androgenetic alopecia, alopecia areata, and chemotherapy-induced alopecia. Revenue generated through fee-for-service contracts. Conducted 30+ studies annually with overseas expansion via Beijing Northland partnership.

epibiotech.com
2Cell Line Sales
TypeOne Time License
Description

Sale of hair follicle cell lines including immortalized DPCs, primary DPCs, primary ORS cells, adipose-derived stem cells, and reporter gene cell lines (STC001-STC011). Cells are sold to research institutions and pharmaceutical companies for in vitro hair loss research.

epibiotech.com
3CDMO (Contract Development and Manufacturing)
TypeProfessional Services
Description

GMP cell therapy manufacturing services for clinical-grade advanced biopharmaceutical production. Includes process development, tech transfer, and manufacturing for cell therapy products. Part of one-stop service from raw material to finished product.

epibiotech.com
4Hair Health Functional Food Evaluation
TypeProfessional Services
Description

Efficacy evaluation services for hair health functional foods following Korean regulatory guidelines. Includes clinical evaluation, nutrient supply, hair cycle regulation, antioxidant, anti-inflammatory, and cell proliferation assessments.

epibiotech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Epibiotech develops novel hair loss therapeutics (cell therapy, antibody, small molecule) using its proprietary Hair.I. AI drug discovery platform, which combines a single-cell hair loss genomic database (EPIGene), multi-target AI screening (AlopeciAI), and preclinical efficacy validation (EPICacy). Beyond internal pipeline development, the company provides preclinical CRO services for hair growth efficacy evaluation, GMP cell therapy CDMO manufacturing, and sells research-grade hair follicle cell lines to pharmaceutical, biotech, and academic customers globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • EPI-005 (CXCL12 neutralizing antibody) showed >6 weeks efficacy with single injection in pig experiments
+5 more records
Product overview1 text field

Epibiotech is Korea's only company exclusively dedicated to hair loss therapeutics and research services, operating a multi-pronged business across drug development, CRO services, and CDMO manufacturing. Its proprietary Hair.I. platform (EPIGene, AlopeciAI, EPICacy) integrates big data genomics, AI-driven drug screening, and preclinical efficacy validation for full-stack hair loss drug discovery. The therapeutic pipeline spans three modalities: cell therapies (EPI-001, autologous dermal papilla cells, Phase 1/2a; EPI-008, allogeneic dermal papilla cells), antibody therapy (EPI-005, CXCL12 neutralizing antibody), and small molecule / drug repurposing (EPI-002, EPI-011 for chemotherapy-induced alopecia). The company operates Korea's leading non-clinical CRO for hair growth efficacy evaluation, offering in vivo, ex vivo, and in vitro services plus single-cell RNA sequencing analysis. A CDMO division provides GMP cell therapy manufacturing. Cell line products (STC001–STC011) covering dermal papilla, ORS, and engineered reporter cell lines are sold for research use. All divisions are unified by the Hair.I. AI platform that powers both internal drug development and client-facing service delivery.

Product and service11 records
1Hair Loss Efficacy CRO Services (EPICacy)
CategoryPreclinical CRO service
Description

Preclinical contract research services for hair growth efficacy evaluation offered to pharmaceutical, biotech, and academic clients. Encompasses in vivo animal models (including Korea's only alopecia areata model), ex vivo human and mouse hair follicle organ culture, and in vitro dermal papilla cell / ORS cell functional assays. The company conducts 30+ contract studies annually for external clients.

2CDMO Services (Cell Therapy Manufacturing)
CategoryCDMO service
Description

Contract development and manufacturing organization services for advanced biopharmaceuticals including cell therapies. Provides GMP clinical-grade manufacturing from raw material through finished product, GMP consulting for clinical entry, and operates a 495m² GMP facility (GMP Suite 1) with culture rooms, separation room, cell bank storage, and QC lab. Holds advanced biopharmaceutical manufacturing license, cell processing facility license, and human cell management business license.

3Hair Follicle Cell Line Products (STC001-STC011)
CategoryResearch cell line product
Description

Eleven hair follicle constituent cell lines sold for research use: immortalized dermal papilla cells (STC001), primary DPC (STC002), primary ORS cells (STC003), adipose-derived stem cells (STC004), β-Catenin-Luc-iDPC (STC005), SOX2-Luc-iDPC (STC006), mouse vibrissa dermal papilla cell line (STC007), β-Catenin-Luc-293T (STC008), SOX2-Luc-293T (STC009), β-Catenin-Luc-HaCaT (STC010), and SOX2-Luc-HaCaT (STC011). Sold to research institutions and pharmaceutical companies for in vitro hair loss research.

4Hair Health Functional Food Evaluation Services
CategoryCRO service
Description

Efficacy evaluation services aligned with Korean health functional food guidelines for hair health. Covers clinical evaluation (in vivo hair growth tests, visual assessment), nutrient supply promotion (IGF-1, HGF, VEGF, EGF markers), hair cycle regulation, antioxidant activity (SOD, CAT, GPx), anti-inflammatory activity (IL-1, TNF-alpha), and cell proliferation (CCK assay). Sold to functional food and cosmetics companies requiring regulatory-compliant efficacy substantiation.

5Single-Cell RNA Sequencing (scRNA-seq) Analysis Services
CategoryCRO / Research service
Description

Single-cell transcriptomics service for hair loss mechanism research and therapeutic development. Analyzes gene expression in diverse follicular cell populations (DP, DF, DS, immune cells) at single-cell resolution, and delivers cell composition changes, ligand-receptor signaling network analysis, disease-specific target discovery, mechanism analysis, and treatment response prediction.

6Hair.I. Integrated Drug Discovery Platform
CategoryAI drug discovery platform
Description

AI-driven integrated hair loss drug discovery platform combining three modules: EPIGene (single-cell hair loss genomic database), AlopeciAI (multi-target AI screening and drug repurposing), and EPICacy (preclinical efficacy validation). Sold to / partnered with global pharma and biotech companies for end-to-end hair loss drug development from target identification through preclinical validation.

7EPI-001 (Autologous Dermal Papilla Cell Therapy)
CategoryTherapeutic pipeline — cell therapy
Description

Autologous dermal papilla cell therapy for androgenetic alopecia. Dermal papilla cells collected from the patient's occipital scalp are mass-cultured and re-injected to stimulate weakened hair follicles and promote new hair growth. Currently in Phase 1/2a clinical trial.

8EPI-008 (Allogeneic Dermal Papilla Cell Therapy)
CategoryTherapeutic pipeline — cell therapy
Description

Allogeneic dermal papilla cell therapy for androgenetic alopecia using cultured allogeneic cells enabling immediate patient use without individual cell harvesting. Cell bank capable of serving 100,000 patients from a single donor.

9EPI-005 (CXCL12 Neutralizing Antibody Therapy)
CategoryTherapeutic pipeline — antibody therapy
Description

CXCL12 neutralizing antibody therapy for androgenetic alopecia and alopecia areata, administered via subcutaneous injection and designed for 4-6 doses per year. Inactivates the CXCL12 hair loss gene, reduces androgen receptor expression in human hair follicles, and demonstrated >6 weeks efficacy with single injection in pig experiments.

10EPI-011 (Chemotherapy-Induced Alopecia Treatment)
CategoryTherapeutic pipeline — small molecule (drug repurposing)
Description

Chemotherapy-induced alopecia (CIA) treatment developed via drug repurposing using the Hair.I. platform. Protects hair follicle microenvironment and regulates inflammatory response under chemotherapy stress conditions.

11EPI-002 (Low Molecular Weight Hair Loss Treatment)
CategoryTherapeutic pipeline — small molecule
Description

Low molecular weight hair loss treatment candidate targeting RIPK1, developed as a topical formulation. Co-developed with QMINE (RIPK1 siRNA-based hair loss therapeutics; MOU signed November 2025). Preclinical studies completed.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Eli Lilly acquired Dice Therapeutics for IL-17 immunology and has a growing dermatology pipeline including baricitinib (used off-label for alopecia areata). Broad incumbent developing autoimmune and dermatology therapies overlapping with hair loss indications.

TypeDirect peer
Description

Aclaris Therapeutics is a US clinical-stage company developing treatments for alopecia areata and androgenetic alopecia, including JAK inhibitors. Comparable to Epibiotech as a small-cap focused hair loss therapeutics developer with multiple candidate modalities.

TypeBroad incumbent
Description

Charles River Laboratories is a global preclinical CRO offering efficacy and safety studies across multiple therapeutic areas. Comparable to Epibiotech's CRO services division, though Charles River operates across many indications beyond hair loss.

TypeDirect peer
Description

Histogen is a US clinical-stage biotech developing novel hair growth treatments including cell-conditioned media and follicle-stimulating approaches. Directly comparable as a small hair loss therapeutics company pursuing regeneration-based therapies.

TypeBroad incumbent
Description

Lonza is the world's largest cell therapy CDMO with extensive GMP manufacturing capacity. Comparable to Epibiotech's CDMO division as a cell therapy contract manufacturer, though Lonza operates at vastly greater scale across multiple modalities.

TypeBroad incumbent
Description

Pfizer has approved Litfulo (ritlecitinib) for alopecia areata and through its acquisition of Arena Pharmaceuticals has a strong dermatology franchise. Represents the major pharma competition and potential exit partner for Epibiotech's hair loss assets.

TypeDirect peer
Description

Stemson Therapeutics is a US-based biotech developing iPSC-derived hair follicle regeneration therapies for hair loss. Directly comparable to Epibiotech's EPI-001/EPI-008 cell therapy approach, both pursuing cell-based hair restoration as a novel therapeutic modality.

TypeBroad incumbent
Description

AbbVie has a major dermatology franchise (Skyrizi, Rinvoq) and through the joint KHIDI-AbbVie Biotech Innovator Award has signaled interest in Epibiotech's EPI-005. Large pharma dermatology incumbent representing both competition and potential licensing partner.

TypeDirect peer
Description

Follica is a clinical-stage biotech developing a hair follicle neogenesis platform for androgenetic alopecia. Directly competes with Epibiotech as a dedicated hair loss therapeutics company pursuing novel mechanisms rather than reformulations of existing drugs.

10Sun Pharmaceutical (Concert Pharmaceuticals)
TypeDirect peer
Description

Sun Pharma acquired Concert Pharmaceuticals and is developing deuruxolitinib for alopecia areata. Directly competes with Epibiotech's antibody therapy approach (EPI-005 CXCL12) in the alopecia areata space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epibiotech

Hair Loss Therapeutics & Preclinical Drug Discovery CROepibiotech.com

Epibiotech is South Korea's only company exclusively dedicated to hair loss therapeutics, operating an AI-driven drug discovery platform (Hair.I.) across cell therapy, antibody, and small molecule pipelines, complemented by a leading domestic non-clinical CRO, CDMO services, and cell line product sales for pharmaceutical and biotech clients globally.

What Epibiotech does

Epibiotech (에피바이오텍, KONEX: 446440) is a South Korean biotech company founded in 2015 (originally as Stemore Co., Ltd., renamed in 2021) that operates as the only Korean firm exclusively dedicated to hair loss therapeutics development. The company is built around its proprietary Hair.I. integrated drug discovery platform, which combines three modules: EPIGene (Korea's only alopecia-specific genomic database with single-cell RNAseq resolution across disease types and species), AlopeciAI (a multi-target AI screening platform with drug repurposing capability), and EPICacy (a hair growth efficacy evaluation platform using Korea's largest collection of alopecia animal models). Epibiotech runs a multi-modality therapeutic pipeline spanning autologous and allogeneic dermal papilla cell therapies (EPI-001 in Phase 1/2a clinical trials; EPI-008 in preclinical with a cell bank scalable to 100,000 patients), a CXCL12 neutralizing antibody (EPI-005), and drug repurposing candidates for chemotherapy-induced alopecia (EPI-011) and topical small molecule treatment (EPI-002).

The company generates revenue across four streams: (1) CRO services for hair growth efficacy evaluation and mechanism studies (30+ contract studies annually, fee-for-service, quote-based pricing), (2) cell line product sales (STC001-STC011 covering dermal papilla cells, ORS cells, adipose-derived stem cells, and engineered reporter cell lines), (3) CDMO services for GMP cell therapy manufacturing from a 495m² GMP facility in Songdo, and (4) hair health functional food evaluation services aligned with Korean regulatory guidelines. Customer segments include pharmaceutical and biotech companies (primary, for preclinical CRO and CDMO), research institutions and academia, and cosmetics and functional food companies. Distribution combines direct B2B field sales, global partnering conference presence (BIO Europe, BIO Japan, WCHR, KDRA), website-based inquiry for CRO/cell line sales, and an exclusive China-market partnership with Beijing Northland. The company holds advanced biopharmaceutical manufacturing, cell processing, and human cell management licenses, has been designated an Outstanding R&D Center by Korea's Ministry of Science and ICT, and has received awards from KHIDI, the Ministry of SMEs and Startups, and AbbVie Korea.

Epibiotech firmographics

Firmographics
Name
Epibiotech
Legal name
주식회사 에피바이오텍 (Epibiotech Co., Ltd.)
Website
https://epibiotech.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Epibiotech is South Korea's only company exclusively dedicated to hair loss therapeutics, operating an AI-driven drug discovery platform (Hair.I.) across cell therapy, antibody, and small molecule pipelines, complemented by a leading domestic non-clinical CRO, CDMO services, and cell line product sales for pharmaceutical and biotech clients globally.
Ownership category
akta.pro rank

Epibiotech industry classification

Industry
Product category
Hair Loss Therapeutics & Preclinical Drug Discovery CRO
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Hair loss therapeutics
  • Drug discovery platform
  • Preclinical CRO services
  • Cell therapy manufacturing
  • Dermal papilla cells

Where Epibiotech is headquartered

Location

Headquarters

HQ city
Incheon
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Epibiotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Revenue model

  1. CRO (Contract Research Organization) Services: Hair growth efficacy evaluation and preclinical research services provided to pharmaceutical companies, biotech firms, and research institutions. Services include in vitro, ex vivo, and in vivo models for androgenetic alopecia, alopecia areata, and chemotherapy-induced alopecia. Revenue generated through fee-for-service contracts. Conducted 30+ studies annually with overseas expansion via Beijing Northland partnership.
  2. Cell Line Sales: Sale of hair follicle cell lines including immortalized DPCs, primary DPCs, primary ORS cells, adipose-derived stem cells, and reporter gene cell lines (STC001-STC011). Cells are sold to research institutions and pharmaceutical companies for in vitro hair loss research.
  3. CDMO (Contract Development and Manufacturing): GMP cell therapy manufacturing services for clinical-grade advanced biopharmaceutical production. Includes process development, tech transfer, and manufacturing for cell therapy products. Part of one-stop service from raw material to finished product.
  4. Hair Health Functional Food Evaluation: Efficacy evaluation services for hair health functional foods following Korean regulatory guidelines. Includes clinical evaluation, nutrient supply, hair cycle regulation, antioxidant, anti-inflammatory, and cell proliferation assessments.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Epibiotech product offering

Product offering

Core offering

Epibiotech develops novel hair loss therapeutics (cell therapy, antibody, small molecule) using its proprietary Hair.I. AI drug discovery platform, which combines a single-cell hair loss genomic database (EPIGene), multi-target AI screening (AlopeciAI), and preclinical efficacy validation (EPICacy). Beyond internal pipeline development, the company provides preclinical CRO services for hair growth efficacy evaluation, GMP cell therapy CDMO manufacturing, and sells research-grade hair follicle cell lines to pharmaceutical, biotech, and academic customers globally.

Product overview

Epibiotech is Korea's only company exclusively dedicated to hair loss therapeutics and research services, operating a multi-pronged business across drug development, CRO services, and CDMO manufacturing. Its proprietary Hair.I. platform (EPIGene, AlopeciAI, EPICacy) integrates big data genomics, AI-driven drug screening, and preclinical efficacy validation for full-stack hair loss drug discovery. The therapeutic pipeline spans three modalities: cell therapies (EPI-001, autologous dermal papilla cells, Phase 1/2a; EPI-008, allogeneic dermal papilla cells), antibody therapy (EPI-005, CXCL12 neutralizing antibody), and small molecule / drug repurposing (EPI-002, EPI-011 for chemotherapy-induced alopecia). The company operates Korea's leading non-clinical CRO for hair growth efficacy evaluation, offering in vivo, ex vivo, and in vitro services plus single-cell RNA sequencing analysis. A CDMO division provides GMP cell therapy manufacturing. Cell line products (STC001–STC011) covering dermal papilla, ORS, and engineered reporter cell lines are sold for research use. All divisions are unified by the Hair.I. AI platform that powers both internal drug development and client-facing service delivery.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hair Loss Efficacy CRO Services (EPICacy) Preclinical contract research services for hair growth efficacy evaluation offered to pharmaceutical, biotech, and academic clients. Encompasses in vivo animal models (including Korea's only alopecia areata model), ex vivo human and mouse hair follicle organ culture, and in vitro dermal papilla cell / ORS cell functional assays. The company conducts 30+ contract studies annually for external clients.
  • CDMO Services (Cell Therapy Manufacturing) Contract development and manufacturing organization services for advanced biopharmaceuticals including cell therapies. Provides GMP clinical-grade manufacturing from raw material through finished product, GMP consulting for clinical entry, and operates a 495m² GMP facility (GMP Suite 1) with culture rooms, separation room, cell bank storage, and QC lab. Holds advanced biopharmaceutical manufacturing license, cell processing facility license, and human cell management business license.
  • Hair Follicle Cell Line Products (STC001-STC011) Eleven hair follicle constituent cell lines sold for research use: immortalized dermal papilla cells (STC001), primary DPC (STC002), primary ORS cells (STC003), adipose-derived stem cells (STC004), β-Catenin-Luc-iDPC (STC005), SOX2-Luc-iDPC (STC006), mouse vibrissa dermal papilla cell line (STC007), β-Catenin-Luc-293T (STC008), SOX2-Luc-293T (STC009), β-Catenin-Luc-HaCaT (STC010), and SOX2-Luc-HaCaT (STC011). Sold to research institutions and pharmaceutical companies for in vitro hair loss research.
  • Hair Health Functional Food Evaluation Services Efficacy evaluation services aligned with Korean health functional food guidelines for hair health. Covers clinical evaluation (in vivo hair growth tests, visual assessment), nutrient supply promotion (IGF-1, HGF, VEGF, EGF markers), hair cycle regulation, antioxidant activity (SOD, CAT, GPx), anti-inflammatory activity (IL-1, TNF-alpha), and cell proliferation (CCK assay). Sold to functional food and cosmetics companies requiring regulatory-compliant efficacy substantiation.
  • Single-Cell RNA Sequencing (scRNA-seq) Analysis Services Single-cell transcriptomics service for hair loss mechanism research and therapeutic development. Analyzes gene expression in diverse follicular cell populations (DP, DF, DS, immune cells) at single-cell resolution, and delivers cell composition changes, ligand-receptor signaling network analysis, disease-specific target discovery, mechanism analysis, and treatment response prediction.
  • Hair.I. Integrated Drug Discovery Platform AI-driven integrated hair loss drug discovery platform combining three modules: EPIGene (single-cell hair loss genomic database), AlopeciAI (multi-target AI screening and drug repurposing), and EPICacy (preclinical efficacy validation). Sold to / partnered with global pharma and biotech companies for end-to-end hair loss drug development from target identification through preclinical validation.
  • EPI-001 (Autologous Dermal Papilla Cell Therapy) Autologous dermal papilla cell therapy for androgenetic alopecia. Dermal papilla cells collected from the patient's occipital scalp are mass-cultured and re-injected to stimulate weakened hair follicles and promote new hair growth. Currently in Phase 1/2a clinical trial.
  • EPI-008 (Allogeneic Dermal Papilla Cell Therapy) Allogeneic dermal papilla cell therapy for androgenetic alopecia using cultured allogeneic cells enabling immediate patient use without individual cell harvesting. Cell bank capable of serving 100,000 patients from a single donor.
  • EPI-005 (CXCL12 Neutralizing Antibody Therapy) CXCL12 neutralizing antibody therapy for androgenetic alopecia and alopecia areata, administered via subcutaneous injection and designed for 4-6 doses per year. Inactivates the CXCL12 hair loss gene, reduces androgen receptor expression in human hair follicles, and demonstrated >6 weeks efficacy with single injection in pig experiments.
  • EPI-011 (Chemotherapy-Induced Alopecia Treatment) Chemotherapy-induced alopecia (CIA) treatment developed via drug repurposing using the Hair.I. platform. Protects hair follicle microenvironment and regulates inflammatory response under chemotherapy stress conditions.
  • EPI-002 (Low Molecular Weight Hair Loss Treatment) Low molecular weight hair loss treatment candidate targeting RIPK1, developed as a topical formulation. Co-developed with QMINE (RIPK1 siRNA-based hair loss therapeutics; MOU signed November 2025). Preclinical studies completed.

Quantifiable outcome

  • EPI-005 (CXCL12 neutralizing antibody) showed >6 weeks efficacy with single injection in pig experiments
  • +5 more outcomes

Companies that use Epibiotech

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Epibiotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Epibiotech partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Epibiotech competitors and assessment

Company assessment

Broad incumbents

  • Eli Lilly: Eli Lilly acquired Dice Therapeutics for IL-17 immunology and has a growing dermatology pipeline including baricitinib (used off-label for alopecia areata). Broad incumbent developing autoimmune and dermatology therapies overlapping with hair loss indications.
  • Charles River Laboratories: Charles River Laboratories is a global preclinical CRO offering efficacy and safety studies across multiple therapeutic areas. Comparable to Epibiotech's CRO services division, though Charles River operates across many indications beyond hair loss.
  • Lonza Group: Lonza is the world's largest cell therapy CDMO with extensive GMP manufacturing capacity. Comparable to Epibiotech's CDMO division as a cell therapy contract manufacturer, though Lonza operates at vastly greater scale across multiple modalities.
  • Pfizer: Pfizer has approved Litfulo (ritlecitinib) for alopecia areata and through its acquisition of Arena Pharmaceuticals has a strong dermatology franchise. Represents the major pharma competition and potential exit partner for Epibiotech's hair loss assets.
  • AbbVie: AbbVie has a major dermatology franchise (Skyrizi, Rinvoq) and through the joint KHIDI-AbbVie Biotech Innovator Award has signaled interest in Epibiotech's EPI-005. Large pharma dermatology incumbent representing both competition and potential licensing partner.

Direct peers

  • Aclaris Therapeutics: Aclaris Therapeutics is a US clinical-stage company developing treatments for alopecia areata and androgenetic alopecia, including JAK inhibitors. Comparable to Epibiotech as a small-cap focused hair loss therapeutics developer with multiple candidate modalities.
  • Histogen: Histogen is a US clinical-stage biotech developing novel hair growth treatments including cell-conditioned media and follicle-stimulating approaches. Directly comparable as a small hair loss therapeutics company pursuing regeneration-based therapies.
  • Stemson Therapeutics: Stemson Therapeutics is a US-based biotech developing iPSC-derived hair follicle regeneration therapies for hair loss. Directly comparable to Epibiotech's EPI-001/EPI-008 cell therapy approach, both pursuing cell-based hair restoration as a novel therapeutic modality.
  • Follica: Follica is a clinical-stage biotech developing a hair follicle neogenesis platform for androgenetic alopecia. Directly competes with Epibiotech as a dedicated hair loss therapeutics company pursuing novel mechanisms rather than reformulations of existing drugs.
  • Sun Pharmaceutical (Concert Pharmaceuticals): Sun Pharma acquired Concert Pharmaceuticals and is developing deuruxolitinib for alopecia areata. Directly competes with Epibiotech's antibody therapy approach (EPI-005 CXCL12) in the alopecia areata space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Epibiotech social profiles

Digital presence

Epibiotech compliance and trust

Trust signal

Compliance12 records

Epibiotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epibiotech leadership team

Management profile

Number of profiles

Profiles2 records

Epibiotech funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epibiotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epibiotech

What does Epibiotech do?

Epibiotech develops novel hair loss therapeutics (cell therapy, antibody, small molecule) using its proprietary Hair.I. AI drug discovery platform, which combines a single-cell hair loss genomic database (EPIGene), multi-target AI screening (AlopeciAI), and preclinical efficacy validation (EPICacy). Beyond internal pipeline development, the company provides preclinical CRO services for hair growth efficacy evaluation, GMP cell therapy CDMO manufacturing, and sells research-grade hair follicle cell lines to pharmaceutical, biotech, and academic customers globally.

Is Epibiotech a public or private company?

Epibiotech is a public company. It is classified as public and is currently operating.

When was Epibiotech founded?

Epibiotech was founded in 2015. It employs 11 to 50 people.

Where is Epibiotech based?

Epibiotech is headquartered in Incheon, South Korea, in the Asia region.

How does Epibiotech make money?

Four revenue lines are on record. CRO (Contract Research Organization) Services are the primary driver. The others are cell Line Sales, CDMO (Contract Development and Manufacturing) and hair Health Functional Food Evaluation.

Who are Epibiotech's main competitors?

Broad incumbents on record are Eli Lilly, Charles River Laboratories, Lonza Group, Pfizer and AbbVie. Direct peers are Aclaris Therapeutics, Histogen, Stemson Therapeutics, Follica and Sun Pharmaceutical (Concert Pharmaceuticals).

Does Epibiotech have an API?

No public API is recorded for Epibiotech.

What industry is Epibiotech in?

Epibiotech's product category is Hair Loss Therapeutics & Preclinical Drug Discovery CRO. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales